Enjoy 20% off your first order · use code Free shipping on orders $100+ · free 2-Day $175+Ships today when you order before 3 PM ET

Purity & COAsNovember 11, 202611 min readCodex Research Team

Are Research Peptides Legal to Buy? U.S. Rules for 2026

Explore products
CR
Codex Research TeamPublished November 11, 2026

11 min read17 cited sources15 FAQs

People ask whether research peptides are legal more than any other question about them. The answer turns on intended use, not on the molecule or the label. This guide sets out the federal rules, what FDA warning letters from 2024 to 2026 relied on, what changed for compounding pharmacies, and what states have done so far.

Key takeaways

  • U.S. law has no category called "research peptides". It regulates drugs, and a peptide is a drug in the legal sense when it is intended for use in people or animals.
  • Intended use is judged by everything a seller says and does. Under 21 CFR § 201.128, that includes labeling, advertising and the circumstances of sale, not only the words on the vial.
  • Seven FDA warning letters from December 2024 to August 2026 rejected "research use only" statements where a website showed the products were meant for human use.
  • The FDA's compounding categories and its July 2026 advisory meeting concern what pharmacies may compound under a prescription. They do not approve any peptide and do not govern laboratory supply.
  • State action in 2026 has addressed licensed clinicians and pharmacies. Louisiana passed a law on compounded peptides, and a California bill on a state research program had not passed as of its last committee action.
Important

Not legal advice. This guide summarizes publicly available U.S. statutes, regulations, FDA documents and state bills for general information, as of November 2026. Laws and enforcement change. Codex Research compounds are not approved by the FDA and are sold for in-vitro laboratory research only, not for human or animal consumption.

Quick answer

U.S. law has no category called "research peptides". Federal law regulates drugs, and a peptide is a drug in the legal sense when it is intended for use in people or animals [1]. Selling a drug for human use without an approved application is unlawful [2]. Supplying the same molecule to a laboratory for in-vitro research is a different activity, and regulations set out a caution statement for materials shipped for that purpose [4].

So the honest answer has three parts:

  1. Intended use decides the legal status, not the molecule and not the label [1, 3].
  2. A "research use only" statement does not protect a seller whose website shows the product is meant for people. Seven FDA warning letters from 2024 to 2026 say so directly [5, 6, 7, 8, 9, 10, 11].
  3. Most of the 2026 news is about compounding pharmacies and clinics, which sit under different rules from laboratory supply [12, 14, 15].

Three kinds of peptide product

Much of the confusion comes from treating three different things as one. The same peptide name can appear in all three columns.

Approved drug Compounded drug Research material
What it is A finished product reviewed and approved by the FDA A preparation made by a licensed pharmacy for a patient A laboratory material supplied for in-vitro research
Who supplies it Manufacturers, through pharmacies Compounding pharmacies and outsourcing facilities Research chemical suppliers
How it reaches someone Prescription Prescription Order for laboratory use
Main rules New drug approval under 21 U.S.C. § 355 [2] Sections 503A and 503B of the same Act, with FDA lists of permitted bulk substances [12] Intended-use rules, and the caution statement in 21 CFR § 312.160 [3, 4]
Approved for use in people Yes, for its labeled use Not FDA-approved as a product No

When someone asks "can you legally buy peptides now?", they are often mixing a question about compounded drugs with a question about research materials. The answers are different.

What federal law regulates

The Federal Food, Drug, and Cosmetic Act defines a drug by what it is intended to do. An article is a drug when it is intended for use in the diagnosis, cure, mitigation, treatment or prevention of disease, or intended to affect the structure or any function of the body [1]. A "new drug" may not be introduced into interstate commerce without an approved application [2].

Two consequences follow.

  • The definition follows the purpose, not the chemistry. A peptide in a vial is not automatically a drug. It becomes one, legally, when it is offered for use in or on a person or an animal.
  • Purpose is read from conduct. 21 CFR § 201.128 says intended use may be shown by labeling claims, advertising matter, and oral or written statements by the seller or its representatives, and by the circumstances surrounding distribution [3].

Take one vial and two sellers.

  • Seller A lists the compound with its sequence, molecular weight, lot number and a certificate of analysis. The page summarizes published laboratory studies and states that the material is for in-vitro research. Nothing on the site describes use in a person.
  • Seller B lists the same compound with the same research-use line. The page describes what the compound does for the person taking it, and the site sells supplies and guides for personal use beside it.

The chemistry is identical. Under 21 CFR § 201.128, the intended use is not [3]. Seller B's product is what the warning letters below describe: an unapproved new drug, whatever the label says.

For materials that stay in the laboratory, 21 CFR § 312.160 describes drugs shipped solely for tests in vitro or in laboratory research animals, and the caution statement those shipments carry [4]. Our guide to what Research Use Only means covers that label in detail.

What FDA warning letters cited, 2024 to 2026

Warning letters are public, and they show how the agency applies the intended-use rule. Each of the seven letters below went to a seller that described its products as for research. In each one, the FDA wrote that, despite those statements, evidence from the seller's website established that the products were intended to be drugs for human use, and it classed them as unapproved new drugs.

Date Recipient What the FDA pointed to
December 10, 2024 Summit Research Peptides [5] Product pages that described the products as drugs acting on the body, beside "research use only" wording
December 10, 2024 Xcel Research LLC [6] Product-page statements about benefits in "research subjects"
February 26, 2025 USApeptide.com [7] Claims on the website; the letter also notes that approved versions of two of the drugs exist, but not the seller's
March 31, 2026 Gram Peptides [8] Product labeling and website content, despite "not intended for human consumption" statements
June 17, 2026 Wholesale Peptide [9] Website and labeling content reviewed in May 2026
August 24, 2026 Peak Performance Peptides [10] Website claims, and a companion product marketed for preparing the peptides for use
August 24, 2026 Royal Peptides LLC [11] Website claims, and companion supplies and how-to resources sold beside the vials

Three patterns run through them.

  • Claims about the body. Describing what a compound does for a person is the most common evidence cited.
  • Disclaimers that contradict the page. A research-use line at the bottom did not outweigh the content above it.
  • Selling the means of personal use. The two August 2026 letters note that supplies and resources offered with the peptides provided the means to prepare a drug for human administration [10, 11].

The lesson for a buyer is practical. How a supplier presents its products is the best public signal of whether it is operating as a research supplier.

Compounding rules are a separate track

A large share of peptide headlines concern compounding: pharmacies preparing a drug for an individual patient under a prescription. The FDA keeps lists of bulk substances nominated for that purpose, sorted into three categories [12].

Category Meaning in FDA's interim policy
Category 1 Bulk substances under evaluation
Category 2 Bulk substances that raise significant safety concerns
Category 3 Substances nominated without adequate support

Several peptides were placed in Category 2 in September 2023, and the FDA publishes its reasons substance by substance [13]. The lists have moved since then. The May 14, 2026 update lists a short set of substances in Category 2 for section 503A, Kisspeptin-10 among them, and notes that GHK-Cu will return to Category 1 for some uses [12]. A number of other peptides now appear on the FDA's page as nominated but withdrawn [13].

On July 23 and 24, 2026, the FDA's Pharmacy Compounding Advisory Committee met to discuss seven peptide-related substances for possible inclusion on the 503A list: BPC-157, KPV, TB-500, MOTS-c, emideltide, Semax and Epitalon [14].

Two points keep this in proportion.

  • These lists govern what a pharmacy may compound. Placement in a category is not an approval and not a ban on a molecule.
  • They do not set the rules for laboratory supply. A research material does not become a medicine because a pharmacy may compound the same substance, and it does not become unlawful because a pharmacy may not.

What states have done in 2026

State law mostly reaches peptides through licensing boards, which regulate physicians, nurses and pharmacists. The clearest 2026 examples concern clinical practice.

  • Louisiana. Senate Bill 253, effective August 1, 2026, provides that licensing boards may not prohibit licensed prescribers from providing peptides to patients, or licensed pharmacists from compounding and dispensing them, where the peptides come from compounding facilities that comply with federal rules [15, 16]. A trade association summary notes that the law defers to federal rules and the standard of care, and does not expand anyone's scope of practice [16].
  • California. Assembly Bill 2442 would create a state program for peptide research and supervised investigational access, with reporting to the Department of Public Health. It was introduced in February 2026 and referred to committee, and it had not become law as of its last listed action [17].

Neither measure covers research materials sold for laboratory use. The federal framework above applies in every state, and a state can add rules of its own. For anything beyond laboratory research, check current law where you are.

A timeline, 2023 to 2026

The events people cite as "peptides were banned" or "peptides are legal again" are the entries below. Most concern compounding or enforcement against specific sellers.

Date What happened Who it affects
September 29, 2023 FDA places several peptides in Category 2 of its interim compounding policies [13] Compounding pharmacies and outsourcing facilities
December 10, 2024 FDA sends warning letters to Summit Research Peptides and Xcel Research [5, 6] Online sellers presenting products for human use
February 26, 2025 FDA sends a warning letter to USApeptide.com [7] Online sellers
March 31, 2026 FDA sends a warning letter to Gram Peptides [8] Online sellers
May 14, 2026 FDA updates its list of bulk substances nominated under section 503A [12] Compounding pharmacies
June 17, 2026 FDA sends a warning letter to Wholesale Peptide [9] Online sellers
July 23 and 24, 2026 FDA's Pharmacy Compounding Advisory Committee discusses seven peptide-related substances [14] Compounding pharmacies
August 1, 2026 Louisiana Senate Bill 253 takes effect [15] Louisiana prescribers and pharmacists
August 24, 2026 FDA sends warning letters to Peak Performance Peptides and Royal Peptides [10, 11] Online sellers

None of these entries approved a research material for use in people, and none made laboratory research with a peptide unlawful.

What this means if you buy for a laboratory

For a research buyer, the legal questions and the quality questions point to the same checks.

  • Read the product pages. They should describe the material and summarize published laboratory research. They should not describe personal results.
  • Ask for the certificate of analysis for your lot. A real one names the laboratory and matches the lot number on the vial. Our guide to spotting a fake COA lists what to look for.
  • Read the terms of sale. A research supplier states that products are for laboratory research and sets expectations for buyers.
  • Keep records. Order confirmations, certificates and lot numbers belong in the laboratory's files.
  • Keep the material in the laboratory. Research materials are not for human or animal use.

Delivery works the same way in every state we ship to. Our shipping guides cover timing and packaging by state and city, including Texas, Florida, New York and California.

How to read a supplier's website the way a regulator would

The warning letters give a buyer a usable test. Open the supplier's site and look for four things.

  1. What the product pages talk about. A research supplier describes the material: identity, purity, lot and published laboratory findings. A page that describes results for a person is what the FDA quoted in its letters [5, 6, 8].
  2. What is sold beside the vials. The August 2026 letters treated companion supplies and how-to resources for personal use as evidence of intent [10, 11].
  3. Whether the page agrees with its own disclaimer. A research-use statement that the rest of the page contradicts carried no weight in any of the seven letters.
  4. Whether the paperwork is real. A certificate of analysis should name the testing laboratory and match the lot on the vial. Our guides to HPLC and mass spectrometry and purity grades explain what a certificate should show.

A supplier that passes all four is treating research use as a rule it follows, not a phrase it prints.

What this guide does not cover

Three questions sit outside this article, and each has its own body of rules.

  • Controlled substance schedules. Scheduling is set by separate federal and state law and can change. Check the current schedules for any compound you work with.
  • Imports. Materials entering the United States are subject to FDA and customs review at the border. Our guide to U.S.-made and imported peptides covers why origin matters.
  • Institutional and sporting rules. Universities, employers and sports bodies set their own policies, which can be stricter than the law.

Common misconceptions

"Research use only on the label makes it legal." The label states the intended use. It does not override a website that shows a different one [3, 5, 8].

"The FDA banned peptides." The Category 2 policy tells compounders which bulk substances raise safety concerns. It is not a prohibition on a molecule, and the lists have changed since 2023 [12, 13].

"If a pharmacy can compound it, the research version is approved too." Compounding eligibility and research supply are separate. Neither one is FDA approval of a product [12].

"State law decides it." The core rules are federal. State boards add rules for the professionals they license [15, 16].

"Purity makes it lawful." Quality and legal status are different questions. A certificate shows what is in the vial. It says nothing about what the vial may be used for.

How Codex Research operates

Codex Research supplies compounds for in-vitro laboratory research only. Our products are not approved by the FDA and are not for human or animal consumption. Product pages summarize published laboratory research rather than personal-use claims, and where a lot's results have been reported, the page shows the lot-specific certificate of analysis so a buyer can document what was received. Questions about a lot, a certificate or our terms can go to info@codexresearch.shop.

Frequently asked questions

Are research peptides legal to buy in the United States?
U.S. law has no category called research peptides. It regulates drugs, and a peptide counts as a drug when it is intended for use in people or animals. Supplying a peptide to a laboratory for in-vitro research is a different activity from selling it for human use, which requires FDA approval. This is general information, not legal advice.
Can you legally buy peptides now?
The federal rules did not change in 2026 for laboratory materials. What changed is enforcement and compounding policy. The FDA sent more warning letters to sellers whose websites showed human use, and it updated its lists of substances that pharmacies may compound under a prescription.
Is a "research use only" label enough to make a sale legal?
No. In seven warning letters from December 2024 to August 2026, the FDA wrote that research-use statements did not change its conclusion, because the sellers' websites established that the products were intended for human use.
Why does intended use matter so much?
Because it is how federal law defines a drug. Under 21 U.S.C. § 321, an article is a drug when it is intended to affect the structure or function of the body or to address disease. The same molecule can sit inside or outside that definition depending on what it is sold for.
How does the FDA decide what a product is intended for?
It looks at the whole picture. 21 CFR § 201.128 says intended use may be shown by labeling claims, advertising, and oral or written statements by the seller, and by the circumstances surrounding the sale.
Did the FDA ban peptides?
No. In 2023 the FDA placed several peptides in a category of bulk substances that it says raise significant safety concerns for compounding. That policy covers compounding. It is not a ban on a molecule, and the lists have changed since, including an update on May 14, 2026.
What changed for compounding pharmacies in 2026?
The FDA updated its nominated-substances list on May 14, 2026, and its Pharmacy Compounding Advisory Committee met on July 23 and 24, 2026 to discuss seven peptide-related substances for the 503A list. These steps concern prescription compounding, not laboratory supply.
What is the difference between a research peptide and a compounded peptide?
A compounded peptide is a drug prepared by a licensed pharmacy for a patient under a prescription. A research peptide is a laboratory material supplied for in-vitro work. They are regulated differently, and one cannot stand in for the other.
Do I need a prescription for peptides?
Approved and compounded peptide drugs are dispensed by pharmacies under a prescription. Research materials are not medicines and are not dispensed that way. They are supplied for laboratory research only and are not for use in people or animals.
Are peptides legal in Texas?
The federal rules in this guide apply in Texas as they do in every state. Texas boards license and discipline clinicians and pharmacies. For a specific situation, check current Texas law or ask a lawyer.
Are peptides legal in New York or New Jersey?
The same federal framework applies in both states. State medical and pharmacy boards regulate licensed professionals, and state law can add its own rules, so check current law in your state for anything beyond laboratory research.
What does Louisiana's 2026 peptide law do?
Senate Bill 253, effective August 1, 2026, stops Louisiana licensing boards from prohibiting licensed prescribers and pharmacists from providing or compounding peptides that come from compliant compounding facilities. It concerns clinical practice and does not address research materials.
Can a research peptide be used on people or animals?
No. Research materials are supplied for in-vitro laboratory work. They are not approved by the FDA, and they are not for human or animal consumption.
How can I tell a legitimate research supplier?
Look for a certificate of analysis matched to the lot on the vial, testing by a named independent laboratory, clear research-use terms of sale, and product pages that make no claims about use in people.
Is this article legal advice?
No. It summarizes public statutes, regulations and FDA documents for general information. Laws change, and a lawyer should answer questions about a specific situation.

References

  1. Federal Food, Drug, and Cosmetic Act § 201, 21 U.S.C. § 321, Definitions.
  2. Federal Food, Drug, and Cosmetic Act § 505, 21 U.S.C. § 355, New drugs.
  3. Electronic Code of Federal Regulations. 21 CFR § 201.128, Meaning of "intended uses".
  4. Electronic Code of Federal Regulations. 21 CFR § 312.160, Drugs for investigational use in laboratory research animals or in vitro tests.
  5. U.S. FDA. Warning Letter, Summit Research Peptides, MARCS-CMS 695607, December 10, 2024.
  6. U.S. FDA. Warning Letter, Xcel Research LLC, MARCS-CMS 694608, December 10, 2024.
  7. U.S. FDA. Warning Letter, USApeptide.com, MARCS-CMS 696885, February 26, 2025.
  8. U.S. FDA. Warning Letter, Gram Peptides, MARCS-CMS 721806, March 31, 2026.
  9. U.S. FDA. Warning Letter, Wholesale Peptide, MARCS-CMS 729447, June 17, 2026.
  10. U.S. FDA. Warning Letter, Peak Performance Peptides, MARCS-CMS 735127, August 24, 2026.
  11. U.S. FDA. Warning Letter, Royal Peptides LLC, MARCS-CMS 734884, August 24, 2026.
  12. U.S. FDA. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act. Updated May 14, 2026.
  13. U.S. FDA. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks.
  14. U.S. FDA. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee.
  15. Louisiana Legislature. Senate Bill 253, 2026 Regular Session (reengrossed text and digest).
  16. American Med Spa Association. New Louisiana Peptide Protections. August 13, 2026.
  17. CalMatters Digital Democracy. AB 2442: Peptides, 2025-2026 session.
For research use only. This article summarizes published laboratory and preclinical literature for reference. It is not medical advice. Codex Research products are not FDA approved and are not for human or animal consumption or for any clinical or medical use.

Shop the lab

Popular research peptides

BPC-157Repair

Research peptide

BPC-157

Tissue-Repair Research

BPC-157 is a 15-amino-acid synthetic peptide taken from a gastric-juice protein, studied in endothelial, fibroblast and growth-factor research. Lot-tested by HPLC and LC-MS.

99%+Purity+149Reward pts
$59.99
View product
TB-500Repair

Research peptide

TB-500

Tissue-Repair Research

TB-500 is Ac-LKKTETQ, the acetylated actin-binding fragment of Thymosin Beta-4 (residues 17–23), supplied as a lyophilized peptide for actin-regulation and cell-migration research.

99%+Purity+187Reward pts
$74.99
View product
GHK-CuDermal

Research peptide

GHK-Cu

Dermal Matrix Research

GHK-Cu is the copper(II) complex of the tripeptide Gly-His-Lys, a constituent of human plasma, studied in fibroblast matrix and copper-transport research. Lot-tested by HPLC.

99%+Purity+99Reward pts
$39.99
View product
GlowBlends

Research peptide

Glow

Repair Blend

Glow is a three-peptide research blend: 49.87 mg GHK-Cu, 9.88 mg BPC-157 and 9.32 mg TB-500 per vial on the current lot, measured by HPLC and tested on a full safety panel.

99%+Purity+237Reward pts
$94.99
View product
NAD+Cellular

Research peptide

NAD+

Cellular Research

NAD+ is nicotinamide adenine dinucleotide, the oxidized redox coenzyme and sirtuin substrate, supplied as lyophilized powder in 500 mg and 1000 mg vials. Lot-tested by LC-MS.

99%+Purity+224Reward pts
$89.99
View product
KlowBlends

Research peptide

Klow

Repair Blend

Klow is a four-peptide research blend: 51.33 mg GHK-Cu, 11.55 mg KPV, 9.32 mg TB-500 and 8.00 mg BPC-157 per vial on the current lot, for multi-pathway laboratory research.

99%+Purity+249Reward pts
$99.99
View product
Melanotan IIDermal

Research peptide

Melanotan II

Melanocortin Research

Melanotan II is a cyclic lactam analog of alpha-MSH that binds the melanocortin receptors, lot-tested at 99.91% purity with a published certificate.

99%+Purity+112Reward pts
$44.99
View product
IpamorelinGH axis

Research peptide

Ipamorelin

GH-Axis Research

Ipamorelin is a five-residue synthetic peptide, Aib-His-D-2-Nal-D-Phe-Lys-NH2, studied as a selective agonist at the ghrelin receptor. Lot-tested by RP-HPLC.

99%+Purity+87Reward pts
$34.99
View product
SemaxNeuro

Research peptide

Semax

Neuropeptide Research

Semax is a seven-residue ACTH(4-7) analogue with a Pro-Gly-Pro tail, studied in BDNF, trkB and cholinergic-neuron research. 5 mg and 10 mg vials, lot-tested by LC-MS.

99%+Purity+124Reward pts
$49.99
View product
SelankNeuro

Research peptide

Selank

Neuropeptide Research

Selank is a seven-residue tuftsin analogue, Thr-Lys-Pro-Arg-Pro-Gly-Pro, studied in enkephalinase and neurotransmission gene-expression research. Lot-tested by LC-MS.

99%+Purity+112Reward pts
$44.99
View product

Keep reading

Purity & COAs
November 14, 2026

What a Peptide Certificate of Analysis Can't Tell You

A certificate of analysis reports the tests a lab ran on one sample on one date. This guide sets out eight things the page cannot tell you, from untested properties and method blind spots to storage after the test, and names the document that fills each gap.

Read Article
Purity & COAs
November 14, 2026

Matching a Peptide COA to Your Lot Number: What to Check

A certificate of analysis describes one lot. This guide shows which five fields tie a report to the vial in your hand, what the sample ID and received date mean, when one report can cover more than one vial size, and what to do when the lot numbers differ.

Read Article
Purity & COAs
November 14, 2026

How Are Peptides Made? Solid-Phase Synthesis Step by Step

Most synthetic peptides are built one amino acid at a time on a resin bead, a method called solid-phase peptide synthesis. This guide walks through each step, explains why a fraction of a percent of yield per step decides the quality of the result, shows where impurities come from, and follows the peptide from crude product to finished vial.

Read Article

From lab to your door

Every compound.Every lot, proven.

U.S.-made research vials, shipped with lot-matched, lab-tested COAs you can scan straight off the label.